ALK and neuroblastoma: Ten years ago, the identification of activating ALK mutations in a subset of sporadic and familial neuroblastoma cases [2–5] revealed that ALK might represent a bona fide therapeutic target for precision medicine, analogous to other mutated tyrosine kinase receptors involved in various adult cancers.